Difference between revisions of "WIN 55,212-2"

Latest revision as of 21:08, 21 September 2010

WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, that produces effects similar to those of Cannabinoid derivatives such as THC but has an entirely different chemical structure.^[1][2][3]

WIN 55,212-2 is a potent cannabinoid receptor agonist^[4] which has been found to be a potent analgesic^[5] in a rat model of neuropathic pain^[6]. It activates p42 and p44 MAP kinase via receptor-mediated signaling.^[7]

WIN 55,212-2, alongside HU-210 and JWH-133, are implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflamatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

WIN 55212-2 is a full agonist at the CB1 receptor and has higher affinity than THC for the CB₁ receptor.^[8]. WIN 55212-2 produces cannabis-like effects in humans within the oral dosage range of 1 to 3 miligrams however the effects are described as milder and shorter lasting when compared to THC.^{[citation needed]}

External links

• Biomol Win 55,212-2 Data Sheet
• The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. 2006 Jul 18; PubMed:16849427
• JNeurosci.org Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
• New Scientist: Hope for cannabis-based drug for Alzheimer's

References

1. ↑ Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole Analogs: Cannabimimetic Activity of a Class of Compounds Structurally Distinct from Δ⁹-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. 1992; 263(3):1118-1126.
2. ↑ Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T. The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vitro and In Vivo Study. Cerebral Cortex. 2001; (11):728-733.
3. ↑ Zhang, Q; Ma; Iszard; Cole; Wang; Wang (2002). "In vitro metabolism of R(+)-2,3-dihydro-5-methyl-3-(morpholinyl)methylpyrrolo 1,2,3-de1,4-benzoxazinyl-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist". Drug metabolism and disposition: the biological fate of chemicals. 30 (10): 1077–86. doi:10.1124/dmd.30.10.1077. PMID 12228183.  More than one of |author2= and |last2= specified (help); More than one of |author3= and |last3= specified (help); More than one of |author4= and |last4= specified (help); More than one of |author5= and |last5= specified (help); More than one of |author6= and |last6= specified (help) edit
4. ↑ C.C. Felder et al. Mol. Pharmacol. 1995 48 443
5. ↑ I.D. Meng et al. Nature 1998 395 381
6. ↑ U. Herzberg et al. Neurosci. Lett. 1997 221 157
7. ↑ M. Bouaboula et al. Biochem. J. 1995 312 637
8. ↑ Kuster, JE; Stevenson, JI; Ward, SJ; D'Ambra, TE; Haycock, DA (1993). "Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids". The Journal of pharmacology and experimental therapeutics. 264 (3): 1352–63. PMID 8450470.  edit
9. ↑ Michalski, C.; Maier, M.; Erkan, M.; Sauliunaite, D.; Bergmann, F.; Pacher, P.; Batkai, S.; Giese, N.; Giese, T. (2008). "Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells". PloS one. 3 (2): e1701. doi:10.1371/journal.pone.0001701. PMC 2253501 Freely accessible. PMID 18301776.  edit